Study Quantifies Health and Economic Burden of Preeclampsia

This article originally appeared here.
Share this content:
Study Quantifies Health and Economic Burden of Preeclampsia
Study Quantifies Health and Economic Burden of Preeclampsia

TUESDAY, July 11, 2017 (HealthDay News) -- Rates of preeclampsia continue to increase in the United States, exacting a significant economic toll, according to a study published online July 11 in the American Journal of Obstetrics and Gynecology.

Researchers examined financial data for the impact of preeclampsia in the first year of life. They put the overall national cost at $1.03 billion for mothers and $1.15 billion for infants. Gestational age at delivery was a major factor in the cost for infants, ranging from $282,570 at less than 28 weeks to $6,013 at 37 or more weeks.

The findings are particularly important because preeclampsia cases rose from 2.4 percent of pregnancies in 1980 to 3.8 percent in 2010, the researchers said. Mothers with preeclampsia and their infants had a significantly increased risk of health complications compared to those without preeclampsia. The average gestational age was reduced by 1.7 weeks in preeclampsia cases.

"Rising rates of preeclampsia threaten the health and well-being of mothers and babies," write the authors of an accompanying editorial. "Although preeclampsia has affected pregnant women for millennia, there is still much we do not know. This new research underscores the urgent need to continue research into its causes and to implement strategies that may help women manage this condition."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Zika Does Not Appear to Last in Semen As Long As Thought

Zika Does Not Appear to Last in Semen ...

More research is needed to better inform public health recommendations

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke Risk

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke ...

I-131 therapy group showed no significantly higher risk of ischemic or hemorrhagic stroke

Higher Odds of Infection With Reduced Kidney Function

Higher Odds of Infection With Reduced Kidney Function

Study finds excess community-acquired infections incidence in individuals with mild to severe CKD

is free, fast, and customized just for you!

Already a member?

Sign In Now »